As 25-year old Jonathan watches Steph Curry sink three point shots for the Golden State Warriors in the 2019 NBA Finals, he can’t believe that Curry was recently diagnosed with keratoconus. Jonathan is also living with this progressive condition and over the last few years has struggled to see anything at a distance.
Growing up, Jonathan didn’t wear glasses or contacts, but one day suddenly noticed he was having trouble seeing things far away. He went for an eye exam, and in 2018, Jonathan found himself on an unexpected journey: he was living with keratoconus. Diagnosed with keratoconus in both eyes, Jonathan was referred to a keratoconus specialist where he learned about FDA approved corneal cross-linking. The goal of cross-linking is intended to slow or halt the progression of keratoconus, a disease that if left untreated, can lead to corneal transplant in about 20 percent of cases1.
NBC Boston recently spoke with Jonathan and his physician Dr. Michael Raizman to discuss Jonathan’s experiences living with keratoconus and the reason he underwent the first and only FDA approved therapeutic treatment to slow the progression of keratoconus.
Watch the full video below:
The results described on this site are based on data collected regarding short- and intermediate-term efficacy of treatment. Individual results are not guaranteed and may vary.
1Borderie VM, Boelle PY, Touzeau O, et al. Predicted long-term Outcome of corneal transplantation. Ophthalmology 2009;2354-2360 Eye Bank Association of America Statistical report, 2016.